Akebia Therapeutics, Inc. (AKBA)
0.865
-0.01
(-0.69%)
USD |
NASDAQ |
Oct 02, 16:00
0.85
-0.02
(-1.73%)
After-Hours: 20:00
Akebia Therapeutics Gross Profit Margin (Quarterly) : 77.59% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 77.59% |
| March 31, 2026 | 76.43% |
| December 31, 2025 | 77.69% |
| September 30, 2025 | 83.49% |
| June 30, 2025 | 83.62% |
| March 31, 2025 | 86.15% |
| December 31, 2024 | 46.45% |
| September 30, 2024 | 61.19% |
| June 30, 2024 | 60.03% |
| March 31, 2024 | 63.29% |
| December 31, 2023 | 66.08% |
| September 30, 2023 | 56.23% |
| June 30, 2023 | 68.64% |
| March 31, 2023 | 48.54% |
| December 31, 2022 | 0.00% |
| September 30, 2022 | 20.57% |
| June 30, 2022 | 84.95% |
| March 31, 2022 | 48.52% |
| December 31, 2021 | 16.66% |
| September 30, 2021 | 78.63% |
| Date | Value |
|---|---|
| June 30, 2021 | -0.15% |
| March 31, 2021 | 32.86% |
| December 31, 2020 | -12.44% |
| September 30, 2020 | 48.56% |
| June 30, 2020 | 33.87% |
| March 31, 2020 | 68.08% |
| December 31, 2019 | 45.11% |
| September 30, 2019 | 58.40% |
| June 30, 2019 | 63.92% |
| March 31, 2019 | 56.38% |
| December 31, 2018 | 86.72% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 99.78% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Emergent BioSolutions, Inc. | 51.22% |
| Exelixis, Inc. | 96.71% |
| ADMA Biologics, Inc. | 69.31% |
| Arcutis Biotherapeutics, Inc. | 91.58% |
| Relay Therapeutics, Inc. | -2.86% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -95.19% |
| Return on Assets | -8.25% |
| Return on Invested Capital | -12.11% |
| Profit Margin (Quarterly) | -18.13% |
| Operating Margin (Quarterly) | -8.92% |
| Return on Net Operating Assets | -21.07% |